database > company
Micromet
Biotech Specialty Pharma
6707, Democracy Blvd., Suite 505
Bethesda, MD 20817 USA
phone:(240) 752-1420
fax:(240) 752-1425
Symbol MITI
Exchange NASDAQ
Founded 1993
Employees
     www.micromet.de
Research Sector Biotech Specialty Pharma
Summary Description
Novel antibody derived therapeutics.
Management
Christian Itin, Ph.D., President, Chief Executive Officer and Director; Barclay A. Phillips, Senior Vice President and Chief Financial Officer; Patrick A. Baeuerle, Ph.D. Professor for Immunology, Senior Vice President and Chief Scientific Officer; Jan Fagerberg, Ph.D., Senior Vice President and Chief Medical Officer; Jens Hennecke, Ph.D., Senior Vice President Business Development
Ownership
Financials


* numbers in thousands
Recent Results
n/a
 
Keywords
lymphomas, leukemias, angiogenic, monoclonal, embryonal


Comment | Printable Version | Modify profile Jan. 14, 2010

Description
Micromet, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer and inflammatory and autoimmune diseases.
Products / Services
A pipeline of drugs to treat cancer, inflammation, and autoimmune disorders.
Technology / Differentiation
BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses mediate the delivery of cytotoxic proteins called perforin and granzymes from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells.
Strategy
Micromet, Inc. was formed in May 2006 through the merger of CancerVax Corporation and Micromet AG, a privately held German company. ==The cCompany has strategic collaborations with Serono, MedImmune, Inc., and Enzon Pharmaceuticals, Inc.
Status
The company currently has two drug candidates, adecatumumab (MT201) and MT103/MEDI-538, in clinical trials against three major cancer indications: prostate cancer, metastatic breast cancer and relapsed non-Hodgkin's lymphoma (NHL). In addition, Micromets pipeline covers four preclinical drug candidates and several compounds at research stage.
Additional Information
On May 5, 2006, CancerVax, Inc. (formerly NASDAQ: CNVX) completed a merger with Micromet AG, or Micromet, a privately-held German company, pursuant to which CancerVax's wholly owned subsidiary, Carlsbad Acquisition Corporation, merged with and into Microm


2010-02-07-687